Articles from Thalia Therapeutics PLC
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
Thalia Therapeutics plc("Thalia" or the "Company")Promising Interim Phase I Data for miRisten™ in Acute Myeloid LeukaemiaPreliminary data show miRisten™ is generally well tolerated, with early indications of biological and clinical activity in interim Phase 1 trial readoutTopline readout targeted for H1 2027First clinical data for Thalia since embarking on its new strategy as a clinical-stage RNA therapeutic company
By Thalia Therapeutics PLC · Via ACCESS Newswire · November 16, 2026
Thalia Therapeutics PLC Announces Acquisition and £2.75 Million Fundraise
Acquisition of oncology company Sanmirna Therapeutics Inc for its clinical-stage Acute Myeloid Leukaemia RNA therapy
By Thalia Therapeutics PLC · Via ACCESS Newswire · June 24, 2026
